Therefore, SAMHD1 inhibition is considered a promising strategy to overcome tumor resistance and SAMHD1 expression has been proposed as a potential biomarker for the stratification of patients with cancer diagnosis that have to be treated with antimetabolites [22]. This evidence concerns the gene SAMHD1 and cancer.